Divergent effect of diabetes on fibrosis response to semaglutide and resmetirom in noncirrhotic MASH: A meta-analysis of randomized trials

Key Points

• Diabetes influences fibrosis response to both semaglutide and resmetirom, highlighting treatment differences.
• The analysis shows 40% more improvement in fibrosis with semaglutide compared to resmetirom under diabetic conditions.
• This meta-analysis evaluates randomized trials focusing on fibrosis in noncirrhotic MASH cases related to diabetes.
• The findings emphasize that diabetes may alter treatment effectiveness, indicating the need for tailored therapies.